Integrative analysis of single-nucleus whole-genome sequencing and bulk tumor tissue enables detection of the subclonal architecture of tumors. Integrative.

Slides:

Advertisements

Similar presentations

Most Random Gene Expression Signatures are Significantly Associated with Breast Cancer Outcome Venet, et al. PLoS Computational Biology, 2011 Molly Carroll.

Advertisements

Shyamala Maherswaran, Ph.D. et al. Sarah Gomez and Rachael Holmes Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.

MDM2: Oncogene Chan Lee. Discovery of MDM2: starting with tumor suppressor p53.

PhyloSub Jiao et. al. BMC Bioinformatics 2014, 15:35.

CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.

Single cell analysis of cancer genomes Peter van Loo and Thierry Voet Jessica Lienesch Lu Lab May 15, 2015.

BNFO 615 Usman Roshan. Projects and papers An opportunity to do hands on work Proposal presentations due by end of September Papers: present at least.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-

The NEW ENGLNAD JOURNAL of MEDICINE 368;18 MARCH 28, 2013

Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach Volker Endris, Roland Penzel,

DNA damage foci in irradiated cells.

by David Grimwade, Adam Ivey, and Brian J. P. Huntly

The cBio Cancer Genomics Portal.

High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer Yu Wu, Jamie R. Schoenborn, Colm Morrissey, Jing Xia, Sandy Larson, Lisha.

Volume 150, Issue 4, Pages (April 2016)

Detection of Low-Level KRAS Mutations Using PNA-Mediated Asymmetric PCR Clamping and Melting Curve Analysis with Unlabeled Probes Ji Eun Oh, Hee Sun.

Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-

Darwinian evolution and tiding clones in multiple myeloma

Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice Stephan Bartels, Sascha Persing, Britta Hasemeier,

Clonal evolution in Ewing sarcoma.

Genomic alterations in breast cancer cell line MDA-MB-231.

Intrinsic and acquired trastuzumab resistance.

Diagnostic approaches to measure the impact of cancer therapies on clonal evolution. Diagnostic approaches to measure the impact of cancer therapies on.

Potential clinical actionability.

Volume 4, Issue 1, Pages 4-6 (July 2003)

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

Volume 17, Issue 6, Pages (June 2013)

Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma

Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low.

Volume 150, Issue 4, Pages (April 2016)

Volume 119, Issue 3, Pages (September 2000)

Diverse abnormalities manifest in RNA

Cancer Evolution: No Room for Negative Selection

Single-Cell Multiomics: Multiple Measurements from Single Cells

Multiplex Amplification Coupled with COLD-PCR and High Resolution Melting Enables Identification of Low-Abundance Mutations in Cancer Samples with Low.

Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-

Evolution of the Cancer Stem Cell Model

Genetic and Functional Diversity of Propagating Cells in Glioblastoma

Identification and characterization of a novel KRAS rearrangement in metastatic prostate cancer. Identification and characterization of a novel KRAS rearrangement.

Inferring Tumor Phylogenies from Multi-region Sequencing

Identification of the CD74–NRG1 fusion gene.

Canonical gliomagenesis mediators EGFR, P53, and retinoblastoma protein (RB1) are important for cancer signaling. Canonical gliomagenesis mediators EGFR,

Temporal order of mutational processes during cancer evolution.

Alternative Classification

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

Practical Bioinformatic DNA-Sequencing Pipeline for Detecting Oncogene Amplification and EGFRvIII Mutational Status in Clinical Glioblastoma Samples

Volume 20, Issue 6, Pages (December 2011)

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Schematics of the computational domain.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

EGFR and cetuximab sensitivity of SCCUAT

CHCHD2 and EGFR protein expression in NSCLC

Targetable alterations and pathways in TNBCs after NAC

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Representative photograph of somatic mutations detected by PCR-SSCP.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Delineating cancer evolution with single-cell sequencing

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

p53 loss affects several steps of the metastatic process.

Frequent coamplification of RTKs in MET-amplified EGC

Strategies for personalized precision immunotherapy.

Volume 12, Issue 6, Pages (December 2007)

A variety of ROS1 gene fusions occur across multiple tumor types.

Integrated analysis of gene expression and copy number alterations.

Presentation transcript:

Integrative analysis of single-nucleus whole-genome sequencing and bulk tumor tissue enables detection of the subclonal architecture of tumors. Integrative analysis of single-nucleus whole-genome sequencing and bulk tumor tissue enables detection of the subclonal architecture of tumors. A, schematic view of the analytic approach. B, a schematic view of illustrative GBM cases. Tumor 1 shows linear evolution of a GBM whose cells relatively uniformly contain both amplified wild-type EGFR and EGFRvIII. Tumor 2 shows a far more complex evolutionary path, characterized by the emergence of multiple, independent, mutually exclusive EGFR variants. Tumor 3 represents an alternative scenario, in which individual GBM cells vary in their amplification of EGFR, PDGFRα, and MET. C, genomic alterations: legend. WGA, Whole Genome Amplification based single-nucleus sequencing. Beatrice Gini, and Paul S. Mischel Cancer Discovery 2014;4:876-878 ©2014 by American Association for Cancer Research